Serna Bio

Serna Bio is an early-stage biotech at the forefront of RNA-targeted small molecule discovery, utilizing a proprietary AI-driven platform to explore RNA-small molecule interactions. The company's mission is to unlock a new class of therapeutics by targeting structured RNA elements, thereby addressing disease-causing proteins and pathways previously considered inaccessible. As a private, pre-revenue entity, it is positioned in the high-growth, high-potential field of RNA medicine beyond modalities like ASOs and siRNA. Its success hinges on validating its computational platform and translating its discoveries into a viable preclinical and clinical pipeline.

AI-driven platform integrating RNA structure prediction, computational screening, and machine learning to discover small molecules that target functional 3D structures in RNA, including non-coding RNAs and mRNA regions.

Serna Bio competes in the emerging RNA-targeted small molecule space with companies like Arrakis Therapeutics, Remix Therapeutics, and Skyhawk Therapeutics, all leveraging computational approaches. It also faces indirect competition from established oligonucleotide therapy developers (e.g., Ionis, Alnylam) and large pharma building internal capabilities. Differentiation hinges on the predictive power and scalability of its proprietary AI platform.